French and British scientists have revealed insight into how a critical immune regulatory pathway contributes to the development of multiple sclerosis (MS), potentially paving the way toward future immunotherapies for the debilitating condition.
Dutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
A comprehensive sustainability assessment carried out by Cologne-based nova-Institute shows that first and second-generation bioethanol is feasible for the EUs climate strategy.
The study challenges the tank or table credo of many EU policymakers, which claims biofuels are unsustainable because they use arable land and thus compete with food production.
Swiss cancer antibody-drug conjugate (ADC) developer ADC Therapeutics Sarl (Epalinges) has raised US$200m million through an oversubscribed private placement. Investors include Auven Therapeutics, Redmile, the Wild Family Office and its development partner AstraZeneca.
European Biotech Week:?Highlighting the benefits biotechnology has brought to pharma development, agriculture and – last but not least – the bioeconomy, industry association EuropaBio celebrated the European Biotech Week with an exhibition, Discovering European Biotech Innovation, in the European Parliament in Brussels.
mRNA cancer therapeutics specialist CureVac AG has baged US$50m upfront and is eglible to receive up to US$1.7bn in development milestones plus royalties for the development of five commercial cancer vaccines arising from a new R&D deal with Eli Lilly & Co. Lilly also made an equity investment of €45m.
Belgian Nanobody® producer Ablynx NV said it aims to raise US$175m of its ordinary shares in a global offering, comprised of a public offering of American Depositary Shares ("ADS") in the US and Canada and an offer of ordinary shares in other countries through a private placement.
A complaint against the EMAs handling of a referral procedure relating to potential side effects of Sanofi/MSDs HPV vaccine Gardasil and GSKs HPV jab Cervarix promoted by the Nordic Cochrane Centre and physicians has been rejected by the European Ombudsman.
The European Medicines Agency (EMA) has upgraded Roches Alecensa (Alectinib) from second-line to first-line treatment for patients with locally advanced of metastasing ALK-positive non-small cell lung cancer (NSCLC).
German infection specialist InflaRx (Jena) raised US$55m in a Series D financing co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC to finance its clinical programmes with its lead asset IFX-1.